Afamelanotide is the same core molecule as "Melanotan I", developed into an FDA-approved prescription implant (Scenesse). "MT-1" sold as an injectable research vial is unapproved and untested. Conflating the two is the single most common error in writing about this peptide.
Overview
Melanotan I has exactly one benefit demonstrated in randomised controlled trials, and it is not tanning. As afamelanotide, delivered as a 16 mg bioresorbable subcutaneous implant, it is approved to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). The FDA approved it on 8 October 2019 under NDA 210797 as a new molecular entity with priority review and orphan designation (Drugs@FDA).
That places Melanotan I in this site's highest evidence tier — approved medicine — while simultaneously making it one of the most over-claimed compounds in the peptide catalogue, because the approval covers a rare genetic photodermatosis and nothing else.
The one demonstrated benefit
The pivotal evidence is a pair of multicenter, randomised, double-blind, placebo-controlled trials published in the New England Journal of Medicine: 74 patients in the European Union and 94 in the United States, randomised 1:1 to a 16 mg afamelanotide implant or placebo every 60 days — five implants over 180 days in the EU study, three over 270 days in the US study. The primary endpoint was hours of direct sun exposure without pain (Langendonk, Balwani et al., NEJM 2015; ClinicalTrials.gov NCT01605136 and NCT00979745).
- US study, 6 months: median pain-free time 69.4 hours with afamelanotide versus 40.8 hours with placebo (P=0.04).
- EU study, 9 months: median 6.0 hours versus 0.8 hours (P=0.005).
- Phototoxic reactions in the EU study: 77 with afamelanotide versus 146 with placebo (P=0.04).
- Quality of life improved in both trials; adverse events were mostly mild.
The EU numbers deserve a second look, because they show what this condition actually is. Nine months of treatment moved the median patient from 0.8 hours of pain-free sunlight to 6.0 hours. That is a meaningful change for someone who cannot go outside — and it is nothing like a tanning outcome.
Why the indication is pain, not tanning
Erythropoietic protoporphyria is an inherited disorder in which protoporphyrin accumulates and reacts to light, producing burning, stinging pain in sun-exposed skin, often without visible blistering. The NEJM authors describe it as a severe photodermatosis associated with excruciating pain and markedly reduced quality of life. Patients organise their lives around avoiding daylight.
The endpoint the trials chose — hours outdoors without pain — follows directly from that. Afamelanotide was developed as a photoprotective agent whose measurable benefit is tolerance of light, with increased pigmentation as the mechanism rather than the goal. Its label lists skin hyperpigmentation among adverse reactions, at 4% (Scenesse label, DailyMed). The cosmetic effect that drives the gray market is, on the approved product, a side effect.
The MC1R mechanism, and its limit
Melanotan I is a synthetic analogue of alpha-melanocyte-stimulating hormone with relatively selective activity at the MC1 receptor on melanocytes, driving eumelanin synthesis. Eumelanin absorbs and dissipates ultraviolet energy, which is the physical basis for the photoprotection concept. That selectivity is also what separates it from melanotan-II, whose non-selective melanocortin activity adds appetite, cardiovascular and sexual-arousal effects.
The limit is important: increased pigmentation is not a substitute for sun protection, and no trial has shown that afamelanotide reduces skin cancer risk. Its label instead requires twice-yearly full-body skin examinations, because the drug can darken pre-existing naevi and freckles and 4% of patients in trials developed a melanocytic naevus.
What the approval does not transfer to
None of the above describes a vial of "MT-1" powder. The trials tested a specific manufactured implant releasing a known quantity over 60 days under dermatological supervision, in patients with a diagnosed rare disease. A self-mixed aqueous injection is a different formulation, a different exposure profile, an unverified quantity, and an unmonitored setting.
A 2017 review in the International Journal of Dermatology makes the distinction explicitly: afamelanotide is the only α-MSH analogue that has been through rigorous testing, while unregulated melanotans carry uncertainties about preparation, administration and dosing, and are associated with mole changes and dysplastic naevi in case reports (Habbema et al. 2017). An approval is a statement about a product, not about a molecule.